Glioblastoma multiforme treated by the chemotherapeutic agent temozolomide in vivo: A 4D simulation model of the tumor response

Antipas, VP; Stamatakos, GS; Uzunoglu, NK

dc.contributor.author	Antipas, VP	en
dc.contributor.author	Stamatakos, GS	en
dc.contributor.author	Uzunoglu, NK	en
dc.date.accessioned	2014-03-01T02:43:21Z
dc.date.available	2014-03-01T02:43:21Z
dc.date.issued	2005	en
dc.identifier.issn	05891019	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/31350
dc.subject	Cancer	en
dc.subject	Chemotherapy	en
dc.subject	Glioblastoma multiforme	en
dc.subject	In silico oncology	en
dc.subject	Neovasculature	en
dc.subject	Patient individualized optimization	en
dc.subject	Simulation model	en
dc.subject	Temozolomide	en
dc.subject	Tumor growth	en
dc.subject.other	Drug pharmacokinetics	en
dc.subject.other	Glioblastoma multiforme	en
dc.subject.other	In silico oncology	en
dc.subject.other	Neovasculature	en
dc.subject.other	Patient individualized optimization	en
dc.subject.other	Temozolomide	en
dc.subject.other	Tumor growth	en
dc.subject.other	Cells	en
dc.subject.other	Chemotherapy	en
dc.subject.other	Computer simulation	en
dc.subject.other	Medical imaging	en
dc.subject.other	Optimization	en
dc.subject.other	Pharmacokinetics	en
dc.subject.other	Tumors	en
dc.subject.other	Drug therapy	en
dc.title	Glioblastoma multiforme treated by the chemotherapeutic agent temozolomide in vivo: A 4D simulation model of the tumor response	en
heal.type	conferenceItem	en
heal.identifier.primary	10.1109/IEMBS.2005.1615885	en
heal.identifier.secondary	http://dx.doi.org/10.1109/IEMBS.2005.1615885	en
heal.identifier.secondary	1615885	en
heal.publicationDate	2005	en
heal.abstract	A novel four dimensional, patient specific simulation model of solid tumor response to chemotherapeutic treatment in vivo is presented. The special case of glioblastoma multiforme treated by temozolomide is addressed as a simulation paradigm. The model is based on the patient's imaging, histopathologic and genetic data. For a given drug administration schedule lying within acceptable toxicity boundaries, the concentration of the prodrug and its metabolites within the tumor is calculated as a function of time based on the drug pharamacokinetics. A discretization mesh is superimposed upon the anatomical region of interest and within each geometrical cell of the mesh the most prominent biological ""laws"" are applied. The biological cell fates are predicted based on the drug pharmacodynamics. The outcome of the simulation is a prediction of the spatiotemporal activity of the entire tumor and is virtual reality visualized. A good qualitative agreement of the model's predictions with clinical experience has strengthened the applicability of the approach. Long term clinical and quantitative adaptation and validation as well as modeling the normal tissue reactions are in progress. The proposed model primarily aims at providing a reliable platform for performing patient individualized in silico experiments as a means of chemotherapeutic treatment optimization. © 2005 IEEE.	en
heal.journalName	Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings	en
dc.identifier.doi	10.1109/IEMBS.2005.1615885	en
dc.identifier.volume	7 VOLS	en
dc.identifier.spage	6100	en
dc.identifier.epage	6103	en